Last Updated on June 11, 2020 by The Health Master
BENGALURU – Indian biotech firm Panacea Biotec Ltd said on Wednesday it would partner with U.S.-based Refana Inc to make a potential vaccine for COVID-19.
The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, Panacea said in a statement to stock exchanges.
Also read: What are antibody therapies and who is developing them?
Panacea’s shares jumped 20% in morning trading on India’s National Stock Exchange after the news.
(Reporting by Sachin Ravikumar; Editing by Shailesh Kuber)
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
